Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NCK1 | P16333 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557898 | 0.92 | ALDH1A1 (0.62) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 | |
| SCHEMBL30908140 | 0.84 | ALDH1A1 (0.52) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 | |
| SCHEMBL12565424 | 0.84 | ALDH1A1 (0.52) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 | |
| SCHEMBL30578800 | 0.79 | CYP1A2 (0.54) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 | |
| SCHEMBL30775025 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNAMAPTCYP1A2 | |
| SCHEMBL8344116 | 0.79 | CYP1A2 (0.54) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 | |
| SCHEMBL629503 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNAMAPTCYP1A2 | |
| SCHEMBL29639029 | 0.79 | CYP1A2 (0.54) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 | |
| SCHEMBL6216217 | 0.77 | ALDH1A1 (1.00) | ALDH1A1NQO2KDM4EMAPTCYP1A2 | |
| SCHEMBL19001534 | 0.76 | NQO2 (0.50) | ALDH1A1NQO2KDM4ELMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-107935944-A | With the double aryl ureas quinoxaline derivants of antitumor activity and its synthetic method | 广西师范大学 | 2018-04-20 | — | — | CN | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9856236-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2018-01-02 | — | — | US | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2011053292-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-05 | — | — | WO | disclosed |
| EP-2271650-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| CN-101903372-A | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| CN-1886389-B | Quinoxaline compounds | JANSSEN PHARMACEUTICA NV | 2010-07-21 | — | — | CN | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-1886389-A | Quinoxaline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-27 | — | — | CN | disclosed |
| CN-1213369-A | Quinoxalinedione compound | PFIZER RES & DEV (IE) | 1999-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885NQO2 130/4885KDM4E 3667/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885NQO2 130/4885KDM4E 3667/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 1082/4885NQO2 130/4885KDM4E 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.